JP2002363102A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002363102A5 JP2002363102A5 JP2002100404A JP2002100404A JP2002363102A5 JP 2002363102 A5 JP2002363102 A5 JP 2002363102A5 JP 2002100404 A JP2002100404 A JP 2002100404A JP 2002100404 A JP2002100404 A JP 2002100404A JP 2002363102 A5 JP2002363102 A5 JP 2002363102A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- administered
- drug
- transfer agent
- dosing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical class OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 36
- 229940079593 drug Drugs 0.000 claims 26
- 239000003814 drug Substances 0.000 claims 26
- 239000003795 chemical substances by application Substances 0.000 claims 16
- AJKIRUJIDFJUKJ-UHFFFAOYSA-N taurolidine Chemical group C1NS(=O)(=O)CCN1CN1CNS(=O)(=O)CC1 AJKIRUJIDFJUKJ-UHFFFAOYSA-N 0.000 claims 10
- RJGYJMFQWGPBGM-UHFFFAOYSA-N 1,2,4-thiadiazinane 1,1-dioxide Chemical compound O=S1(=O)CCNCN1 RJGYJMFQWGPBGM-UHFFFAOYSA-N 0.000 claims 8
- 229960004267 taurolidine Drugs 0.000 claims 8
- 229950007343 taurultam Drugs 0.000 claims 6
- 239000000243 solution Substances 0.000 claims 5
- 238000001802 infusion Methods 0.000 claims 4
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims 4
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical group FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 3
- 229960002949 fluorouracil Drugs 0.000 claims 3
- 208000014018 liver neoplasm Diseases 0.000 claims 3
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 claims 2
- 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 239000008151 electrolyte solution Substances 0.000 claims 2
- 229940021013 electrolyte solution Drugs 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 229960003080 taurine Drugs 0.000 claims 2
- MVQXBXLDXSQURK-UHFFFAOYSA-N 2-aminoethanesulfonamide Chemical class NCCS(N)(=O)=O MVQXBXLDXSQURK-UHFFFAOYSA-N 0.000 claims 1
- 206010019695 Hepatic neoplasm Diseases 0.000 claims 1
- 230000003501 anti-edematous effect Effects 0.000 claims 1
- 229940041181 antineoplastic drug Drugs 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 210000001367 artery Anatomy 0.000 claims 1
- 239000012752 auxiliary agent Substances 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000030833 cell death Effects 0.000 claims 1
- 239000000812 cholinergic antagonist Substances 0.000 claims 1
- 210000002767 hepatic artery Anatomy 0.000 claims 1
- 230000002440 hepatic effect Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 210000005170 neoplastic cell Anatomy 0.000 claims 1
- 210000003240 portal vein Anatomy 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 150000003672 ureas Chemical class 0.000 claims 1
Applications Claiming Priority (14)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28074801P | 2001-04-03 | 2001-04-03 | |
| US28171101P | 2001-04-06 | 2001-04-06 | |
| US28171201P | 2001-04-06 | 2001-04-06 | |
| US28171301P | 2001-04-06 | 2001-04-06 | |
| US28171001P | 2001-04-06 | 2001-04-06 | |
| US28493401P | 2001-04-20 | 2001-04-20 | |
| US28493301P | 2001-04-20 | 2001-04-20 | |
| US60/281710 | 2001-04-20 | ||
| US60/281713 | 2001-04-20 | ||
| US60/281712 | 2001-04-20 | ||
| US60/284933 | 2001-04-20 | ||
| US60/280748 | 2001-04-20 | ||
| US60/281711 | 2001-04-20 | ||
| US60/284934 | 2001-04-20 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009022892A Division JP5232678B2 (ja) | 2001-04-03 | 2009-02-03 | 新形成細胞の細胞消滅死を誘導する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002363102A JP2002363102A (ja) | 2002-12-18 |
| JP2002363102A5 true JP2002363102A5 (enExample) | 2005-07-21 |
Family
ID=27569569
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002100404A Pending JP2002363102A (ja) | 2001-04-03 | 2002-04-02 | 新形成細胞の細胞消滅死を誘導する方法 |
| JP2009022892A Expired - Fee Related JP5232678B2 (ja) | 2001-04-03 | 2009-02-03 | 新形成細胞の細胞消滅死を誘導する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009022892A Expired - Fee Related JP5232678B2 (ja) | 2001-04-03 | 2009-02-03 | 新形成細胞の細胞消滅死を誘導する方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20030027818A1 (enExample) |
| EP (2) | EP1247524B1 (enExample) |
| JP (2) | JP2002363102A (enExample) |
| CA (2) | CA2379734C (enExample) |
| ES (2) | ES2562827T3 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8236794B2 (en) | 2003-09-29 | 2012-08-07 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Treatment of mesothelioma |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050124608A1 (en) * | 2001-04-03 | 2005-06-09 | Redmond H. P. | Treatment of cancers |
| US20070275955A1 (en) * | 1997-07-31 | 2007-11-29 | Ed. Geistlich Soehne Ag | Method of treating tumors |
| US8304390B2 (en) * | 1997-07-31 | 2012-11-06 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Method of treatment for preventing or reducing tumor growth in the liver of patient |
| US7345039B2 (en) * | 1999-06-04 | 2008-03-18 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer |
| US8030301B2 (en) * | 1999-06-04 | 2011-10-04 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Treatment of cancers with methylol-containing compounds and at least one electrolyte |
| US6821968B2 (en) | 2001-09-26 | 2004-11-23 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Stable taurolidine electrolyte solutions |
| US7892530B2 (en) * | 1999-06-04 | 2011-02-22 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Treatment of tumor metastases and cancer |
| WO2002044394A2 (en) * | 2000-11-29 | 2002-06-06 | University Of Southern California | Targetet retoviral vectors for cancer immunotherapy |
| US20030092707A1 (en) * | 2001-10-19 | 2003-05-15 | Redmond H. Paul | Treatment of breast cancer |
| US20090123428A1 (en) * | 2003-04-21 | 2009-05-14 | Hall Frederick L | Pathotropic targeted gene delivery system for cancer and other disorders |
| JP2006524057A (ja) * | 2003-04-21 | 2006-10-26 | エペイウス バイオテクノロジーズ， インコーポレイテッド | 疾患を処置するための方法および組成物 |
| US20070178066A1 (en) | 2003-04-21 | 2007-08-02 | Hall Frederick L | Pathotropic targeted gene delivery system for cancer and other disorders |
| TW200730176A (en) * | 2005-11-29 | 2007-08-16 | Novartis Ag | Formulations of quinolinones |
| ES2377206T3 (es) * | 2006-01-06 | 2012-03-23 | Ed Geistlich Sohne Ag Fur Chemische Industrie | Composiciones irradiadas y tratamiento de cánceres con radiación en combinación con taurolidina y/o taurultam |
| WO2008029264A2 (en) * | 2006-09-07 | 2008-03-13 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Method of treating bone cancer |
| EP2575783B1 (en) * | 2010-06-01 | 2017-01-11 | Geistlich Pharma AG | Methods and compositions for oral pharmaceutical therapy |
| EP3344236A4 (en) * | 2015-08-31 | 2019-05-08 | Cormedix Inc. | ADMINISTRATION OF ACTIVE SUBSTANCES WITH NANOFIBLE CARRIAGES |
| US20190381060A1 (en) | 2016-01-11 | 2019-12-19 | Cormedix Inc. | Taurolidine treatment for myc-expressing tumors in mammalian bodies |
| KR20210050544A (ko) * | 2018-08-28 | 2021-05-07 | 코르메딕스, 인코포레이티드 | 타우로리딘 가수분해 생성물을 이용한 신경모세포종 치료 |
| AU2019331913B2 (en) * | 2018-08-31 | 2025-06-26 | Cormedix Inc. | Taurolidine treatment for myc-expressing tumors in mammalian bodies |
| US20220323452A1 (en) * | 2019-05-22 | 2022-10-13 | Geistlich Pharma Ag | Methods and compositions for inhibiting gapdh |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8617482D0 (en) | 1986-07-17 | 1986-08-28 | Geistlich Soehne Ag | Pharmaceutical composition |
| US5210083A (en) | 1986-07-17 | 1993-05-11 | Ed. Geistlich Sohne A.G. Fur Chemische Industrie | Pharmaceutical compositions |
| GB9005856D0 (en) | 1990-03-15 | 1990-05-09 | Geistlich Soehne Ag | Compositions |
| GB9015108D0 (en) * | 1990-07-09 | 1990-08-29 | Geistlich Soehne Ag | Chemical compositions |
| AU641529B2 (en) * | 1990-07-30 | 1993-09-23 | Bloomfield D.A. | Zwitterionic compounds and their N-halo derivatives for use in the treatment of clinical conditions |
| GB9600426D0 (en) * | 1996-01-10 | 1996-03-13 | Ed Geistlich Sohne A G | Compositions |
| US5858990A (en) * | 1997-03-04 | 1999-01-12 | St. Elizabeth's Medical Center | Fas ligand compositions for treatment of proliferative disorders |
| WO1998052573A1 (en) | 1997-05-20 | 1998-11-26 | Galenica Pharmaceuticals, Inc. | Triterpene saponin analogs having adjuvant and immunostimulatory activity |
| WO1998052572A1 (en) * | 1997-05-22 | 1998-11-26 | Oklahoma Medical Research Foundation | Use of taurolidine for treatment of leukemias |
| GB9716219D0 (en) * | 1997-07-31 | 1997-10-08 | Geistlich Soehne Ag | Prevention of metastases |
| US6479481B1 (en) * | 1999-06-04 | 2002-11-12 | Ed. Geistlich Soehne Ag Fur Chemische Industrie | Methods and compositions for treating primary and secondary tumors of the central nervous system (CNS) |
| CA2393252A1 (en) | 1999-12-06 | 2001-06-07 | Paul Calabresi | Use of methylol-containing compounds to treat tumors |
| CA2363973C (en) * | 2000-11-28 | 2009-03-10 | Ed. Geistlich Sohne Ag Fur Chemische Industrie | Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer |
| UA77200C2 (en) * | 2001-08-07 | 2006-11-15 | Wyeth Corp | Antineoplastic combination of cci-779 and bkb-569 |
-
2002
- 2002-03-29 US US10/109,058 patent/US20030027818A1/en not_active Abandoned
- 2002-04-02 CA CA2379734A patent/CA2379734C/en not_active Expired - Lifetime
- 2002-04-02 CA CA2692295A patent/CA2692295C/en not_active Expired - Lifetime
- 2002-04-02 JP JP2002100404A patent/JP2002363102A/ja active Pending
- 2002-04-03 EP EP02252414.4A patent/EP1247524B1/en not_active Expired - Lifetime
- 2002-04-03 ES ES10009649.4T patent/ES2562827T3/es not_active Expired - Lifetime
- 2002-04-03 ES ES02252414.4T patent/ES2542842T3/es not_active Expired - Lifetime
- 2002-04-03 EP EP10009649.4A patent/EP2258373B1/en not_active Expired - Lifetime
-
2009
- 2009-02-03 JP JP2009022892A patent/JP5232678B2/ja not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8236794B2 (en) | 2003-09-29 | 2012-08-07 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Treatment of mesothelioma |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002363102A5 (enExample) | ||
| JP2009138003A5 (enExample) | ||
| EP3173100B1 (en) | Therapeutic combination comprising a cdks inhibitor and oxaliplatin | |
| CA2379734A1 (en) | Treatment of cancers | |
| AU726089B2 (en) | Use of pyrimidine derivatives for the prevention of cancer, on their own or in combination with other therapeutic measures | |
| JP2007515469A5 (enExample) | ||
| CN113056272A (zh) | 新的喹唑啉egfr抑制剂 | |
| FI3463345T3 (fi) | Farmaseuttisia yhdistelmiä | |
| JPH05500973A (ja) | 化学的組成物 | |
| JP2019526559A5 (enExample) | ||
| JP2005517040A5 (enExample) | ||
| MX2008016125A (es) | Compuestos organicos. | |
| EP1208840B1 (en) | Combination of fluorouracil and a methylol transfer agent for the treatment of tumor metastases and cancer | |
| CN114469955B (zh) | 喹唑啉衍生物在制备预防和/或治疗胃肠道疾病药物中的应用 | |
| Love et al. | Glucagon therapy in the treatment of symptomatic bradycardia | |
| CA2482687A1 (en) | Treatment of mesothelioma | |
| CN101185627A (zh) | 一种治疗实体肿瘤的尼罗替尼缓释植入剂 | |
| JPH06505741A (ja) | 非小細胞肺癌の治療 | |
| JP2020512408A5 (enExample) | ||
| CN113925850A (zh) | D-甘露糖促进三阴性乳腺癌的免疫治疗和放疗的用途 | |
| CN101181232B (zh) | 一种治疗实体肿瘤的马赛替尼缓释植入剂 | |
| ANDERSON et al. | Parenteral administration of a watersoluble compound with vitamin k activity: 4-amino-2-methyl-1-naphthol hydrochloride | |
| Benahmed et al. | Cis platine (CDDP) in continuous intravenous ambulatory infusion: a new method of administration | |
| CN108042545B (zh) | 盐酸氮卓斯汀在制备抑制结肠癌肿瘤生长药物中的应用 | |
| VANDER VEER et al. | Clinical experiences with a new mercurial diuretic for subcutaneous administration |